Upkara is developing novel biopreservation technologies for the stabilization of a variety of biopharmaceuticals including proteins, nucleic acids, viruses and cells. The technology is broadly applicable and we are currently evaluating opportunities within the analytical testing, diagnostic testing and human medicine markets with the aim of global commercialization and elimination of cold-chain requirements. Ultimately, Upkara desires that our technology has a strong social impact by enabling the delivery of life-saving medicines to regions lacking the critical infrastructure required for medical storage.
Location: United States, Michigan, Ann Arbor
Employees: 11-50
Total raised: $9M
Founded date: 2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2023 | Series A | $9M | - |
Mentions in press and media 3
| Date | Title | Description |
| 16.05.2023 | Upkara Raises $9M in Series A Funding | Upkara, an Ann Arbor, MI-based biomedical technology company, raised $9M in Series A funding. Backers included Bill Parfet, and Paul Meister. The company intends to use the funds to accelerate its growth trajectory, and continue to develop ... |
| - | Upkara | “Upkara is revolutionizing the biomedical industries by eliminating cold-chain. Our innovative biopreservation technology improves access to therapeutics and research tools by enabling ambient temperature storage and transportation.” |
| - | Upkara | “Upkara aims to eliminate the cold-chain requirements of therapeutics, vaccines and reagents with its innovative, patented biopreservation...” |